Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy

Area of Science:

• Oncology
• Immunology
• Cancer Therapeutics

Background:

• Immune checkpoint blockade (ICB) has transformed cancer treatment, yet response rates remain limited.
• Identifying predictive biomarkers and overcoming resistance are critical challenges in ICB therapy.

Purpose of the Study:

• To review the predictive role of the tumor microenvironment in ICB response.
• To discuss therapeutic strategies for enhancing ICB efficacy.
• To propose a personalized, biomarker-based adaptive immunotherapy approach.

Main Methods:

• Literature review of current research on tumor microenvironment characteristics and ICB.
• Analysis of therapeutic strategies aimed at modifying the tumor microenvironment.
• Conceptualization of a personalized adaptive immunotherapy model.

Main Results:

• The tumor microenvironment significantly influences ICB response.
• Therapeutic interventions can potentially convert non-responsive tumors into ICB-sensitive ones.
• A personalized, adaptive approach integrating biomarker monitoring may improve treatment outcomes.

Conclusions:

• Understanding the tumor microenvironment is key to improving ICB efficacy.
• Tailoring sensitizing therapies based on specific tumor microenvironment biomarkers can enhance patient response.
• Personalized, adaptive immunotherapy holds potential for broader application of ICB.